TARS Long Put Strategy
TARS (Tarsus Pharmaceuticals, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
TARS (Tarsus Pharmaceuticals, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.71B, a beta of 0.51 versus the broader market, a 52-week range of 38.51-85.25, average daily share volume of 636K, a public-listing history dating back to 2020, approximately 323 full-time employees. These structural characteristics shape how TARS stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.51 indicates TARS has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on TARS?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current TARS snapshot
As of June 30, 2026, spot at $63.02, ATM IV 79.60%, IV rank 18.92%, expected move 22.82%. The long put on TARS below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long put structure on TARS specifically: TARS IV at 79.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a TARS long put, with a market-implied 1-standard-deviation move of approximately 22.82% (roughly $14.38 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated TARS expiries trade a higher absolute premium for lower per-day decay. Position sizing on TARS should anchor to the underlying notional of $63.02 per share and to the trader's directional view on TARS stock.
TARS long put setup
The TARS long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With TARS near $63.02, the first option leg uses a $62.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed TARS chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 TARS shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $62.50 | $4.35 |
TARS long put risk and reward
- Net Premium / Debit
- -$435.00
- Max Profit (per contract)
- $5,814.00
- Max Loss (per contract)
- -$435.00
- Breakeven(s)
- $58.15
- Risk / Reward Ratio
- 13.366
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
TARS long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on TARS. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$5,814.00 |
| $13.94 | -77.9% | +$4,420.70 |
| $27.88 | -55.8% | +$3,027.41 |
| $41.81 | -33.7% | +$1,634.11 |
| $55.74 | -11.5% | +$240.81 |
| $69.67 | +10.6% | -$435.00 |
| $83.61 | +32.7% | -$435.00 |
| $97.54 | +54.8% | -$435.00 |
| $111.47 | +76.9% | -$435.00 |
| $125.41 | +99.0% | -$435.00 |
When traders use long put on TARS
Long puts on TARS hedge an existing long TARS stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying TARS exposure being hedged.
TARS thesis for this long put
The market-implied 1-standard-deviation range for TARS extends from approximately $48.64 on the downside to $77.40 on the upside. A TARS long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long TARS position with one put per 100 shares held. Current TARS IV rank near 18.92% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on TARS at 79.60%. As a Healthcare name, TARS options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to TARS-specific events.
TARS long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. TARS positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move TARS alongside the broader basket even when TARS-specific fundamentals are unchanged. Long-premium structures like a long put on TARS are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current TARS chain quotes before placing a trade.
Frequently asked questions
- What is a long put on TARS?
- A long put on TARS is the long put strategy applied to TARS (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With TARS stock trading near $63.02, the strikes shown on this page are snapped to the nearest listed TARS chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are TARS long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the TARS long put priced from the end-of-day chain at a 30-day expiry (ATM IV 79.60%), the computed maximum profit is $5,814.00 per contract and the computed maximum loss is -$435.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a TARS long put?
- The breakeven for the TARS long put priced on this page is roughly $58.15 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current TARS market-implied 1-standard-deviation expected move is approximately 22.82%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on TARS?
- Long puts on TARS hedge an existing long TARS stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying TARS exposure being hedged.
- How does current TARS implied volatility affect this long put?
- TARS ATM IV is at 79.60% with IV rank near 18.92%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.